Endevica Bio
Endevica Bio is committed to pioneering science-driven solutions in peptide therapeutics, focusing on treatments for cachexia, obesity, and metabolic disorders. The company develops first-in-class peptide drug candidates that target complex conditions with innovative approaches, aiming to transform patient outcomes and address unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Endevica Bio
Columbia, Missouri, United States, North America
Products
CNS-penetrant peptide candidate for prevention of cancer-related weight loss (melanocortin‑3/4 antagonist)
Clinical-stage peptide therapeutic designed to cross the blood–brain barrier and modulate central melanocortin pathways to prevent chemotherapy- and disease-associated weight loss and preserve lean mass; completed Phase 1 and entered Phase 2 clinical testing in metastatic colorectal cancer patients.
Orally dosed peptide candidate for obesity and weight modulation (melanocortin receptor agonist)
Preclinical oral peptide agonist targeting central melanocortin pathways shown in animal studies to induce durable weight loss, reduce caloric intake, and preserve muscle mass; non-human primate and rodent efficacy data reported.
CNS-penetrant peptide candidate for prevention of cancer-related weight loss (melanocortin‑3/4 antagonist)
Clinical-stage peptide therapeutic designed to cross the blood–brain barrier and modulate central melanocortin pathways to prevent chemotherapy- and disease-associated weight loss and preserve lean mass; completed Phase 1 and entered Phase 2 clinical testing in metastatic colorectal cancer patients.
Orally dosed peptide candidate for obesity and weight modulation (melanocortin receptor agonist)
Preclinical oral peptide agonist targeting central melanocortin pathways shown in animal studies to induce durable weight loss, reduce caloric intake, and preserve muscle mass; non-human primate and rodent efficacy data reported.
Services
Clinical development and trial execution
Design and conduct of first-in-human and multi-site Phase 2 clinical studies for peptide therapeutics, including regulatory interactions and CRO partnerships.
Clinical development and trial execution
Design and conduct of first-in-human and multi-site Phase 2 clinical studies for peptide therapeutics, including regulatory interactions and CRO partnerships.
Expertise Areas
- Peptide therapeutics
- Central nervous system (CNS)–targeted drug design
- Cachexia drug development
- Obesity and metabolic disorder therapeutics
Key Technologies
- Peptidomimetics and peptide engineering
- Blood–brain barrier penetration strategies
- Melanocortin receptor modulation (MC3/4 targeting)
- Oral peptide delivery/formulation